This company has been marked as potentially delisted and may not be actively trading. Lionheart Acquisition Co. II (LCAP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LCAP vs. ARDT, CNTA, ARWR, HRMY, QDEL, GLPG, BCRX, ARQT, AGIO, and IDYAShould you be buying Lionheart Acquisition Co. II stock or one of its competitors? The main competitors of Lionheart Acquisition Co. II include Ardent Health Partners (ARDT), Centessa Pharmaceuticals (CNTA), Arrowhead Pharmaceuticals (ARWR), Harmony Biosciences (HRMY), QuidelOrtho (QDEL), Galapagos (GLPG), BioCryst Pharmaceuticals (BCRX), Arcutis Biotherapeutics (ARQT), Agios Pharmaceuticals (AGIO), and IDEAYA Biosciences (IDYA). These companies are all part of the "medical" sector. Lionheart Acquisition Co. II vs. Ardent Health Partners Centessa Pharmaceuticals Arrowhead Pharmaceuticals Harmony Biosciences QuidelOrtho Galapagos BioCryst Pharmaceuticals Arcutis Biotherapeutics Agios Pharmaceuticals IDEAYA Biosciences Ardent Health Partners (NYSE:ARDT) and Lionheart Acquisition Co. II (NASDAQ:LCAP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, community ranking, risk, analyst recommendations and valuation. Do analysts rate ARDT or LCAP? Ardent Health Partners presently has a consensus target price of $20.58, indicating a potential upside of 61.95%. Given Ardent Health Partners' stronger consensus rating and higher possible upside, analysts plainly believe Ardent Health Partners is more favorable than Lionheart Acquisition Co. II.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ardent Health Partners 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Lionheart Acquisition Co. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ARDT or LCAP more profitable? Ardent Health Partners' return on equity of 0.00% beat Lionheart Acquisition Co. II's return on equity.Company Net Margins Return on Equity Return on Assets Ardent Health PartnersN/A N/A N/A Lionheart Acquisition Co. II N/A -44.30%1.39% Does the media favor ARDT or LCAP? In the previous week, Ardent Health Partners had 8 more articles in the media than Lionheart Acquisition Co. II. MarketBeat recorded 8 mentions for Ardent Health Partners and 0 mentions for Lionheart Acquisition Co. II. Ardent Health Partners' average media sentiment score of 1.07 beat Lionheart Acquisition Co. II's score of 0.00 indicating that Ardent Health Partners is being referred to more favorably in the media. Company Overall Sentiment Ardent Health Partners Positive Lionheart Acquisition Co. II Neutral Which has better earnings and valuation, ARDT or LCAP? Ardent Health Partners has higher revenue and earnings than Lionheart Acquisition Co. II. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArdent Health Partners$5.97B0.30$53.90MN/AN/ALionheart Acquisition Co. IIN/AN/A$3.21MN/AN/A Does the MarketBeat Community prefer ARDT or LCAP? Ardent Health Partners received 23 more outperform votes than Lionheart Acquisition Co. II when rated by MarketBeat users. CompanyUnderperformOutperformArdent Health PartnersOutperform Votes2388.46% Underperform Votes311.54%Lionheart Acquisition Co. IIN/AN/A SummaryArdent Health Partners beats Lionheart Acquisition Co. II on 10 of the 11 factors compared between the two stocks. Get Lionheart Acquisition Co. II News Delivered to You Automatically Sign up to receive the latest news and ratings for LCAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LCAP vs. The Competition Export to ExcelMetricLionheart Acquisition Co. IIBusiness Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$454.52M$149.06M$5.56B$7.83BDividend YieldN/AN/A5.11%4.22%P/E RatioN/A0.7722.4818.48Price / SalesN/A29.24395.10103.59Price / Cash20.6411.7038.1834.62Price / Book-8.643.886.774.25Net Income$3.21M$1.30M$3.22B$248.23M Lionheart Acquisition Co. II Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LCAPLionheart Acquisition Co. IIN/A$24.63+0.3%N/A+2,432.0%$454.52MN/A0.003ARDTArdent Health Partners2.7315 of 5 stars$11.77+1.6%$20.58+74.9%N/A$1.68B$5.97B0.0024,200Upcoming EarningsAnalyst RevisionPositive NewsCNTACentessa Pharmaceuticals2.5587 of 5 stars$12.56+3.4%$27.71+120.6%+49.7%$1.67B$6.85M-8.21200News CoveragePositive NewsARWRArrowhead Pharmaceuticals3.6159 of 5 stars$12.13+0.4%$41.44+241.8%-38.6%$1.67B$2.50M-2.35400Upcoming EarningsNews CoveragePositive NewsGap DownHRMYHarmony Biosciences4.8174 of 5 stars$28.76+0.9%$53.33+85.4%-4.7%$1.66B$714.73M13.70200Upcoming EarningsAnalyst ForecastPositive NewsQDELQuidelOrtho4.4388 of 5 stars$24.53-0.1%$46.83+91.0%-31.5%$1.66B$2.78B-0.817,000Upcoming EarningsPositive NewsGLPGGalapagos0.5894 of 5 stars$25.08+1.8%$25.33+1.0%-5.4%$1.65B$275.65M0.001,310Options VolumeBCRXBioCryst Pharmaceuticals4.4622 of 5 stars$7.83+3.9%$15.57+99.0%+114.3%$1.63B$450.71M-12.79530Upcoming EarningsAnalyst ForecastNews CoverageARQTArcutis Biotherapeutics2.7597 of 5 stars$13.74+1.5%$18.80+36.8%+79.2%$1.63B$196.54M-7.68150Upcoming EarningsPositive NewsGap DownAGIOAgios Pharmaceuticals4.3137 of 5 stars$28.10+2.8%$56.57+101.4%-8.6%$1.61B$36.50M2.48390News CoveragePositive NewsIDYAIDEAYA Biosciences3.6806 of 5 stars$18.31+0.7%$53.58+192.7%-50.5%$1.60B$7M-5.5580Upcoming Earnings Related Companies and Tools Related Companies ARDT Alternatives CNTA Alternatives ARWR Alternatives HRMY Alternatives QDEL Alternatives GLPG Alternatives BCRX Alternatives ARQT Alternatives AGIO Alternatives IDYA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LCAP) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lionheart Acquisition Co. II Please log in to your account or sign up in order to add this asset to your watchlist. Share Lionheart Acquisition Co. II With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LCAP Stock Free LCAP Stock Alerts